WEBULL
WebtradeDownload

SimpleScreen CRC Launch Could Be A Big Moment For Abbott Stock

Simply Wall St · 2d ago
  • Abbott Laboratories recently launched Ensure Max Protein 3-in-1 Muscle Support, gained FDA approval for expanded CardioMEMS HF System app capabilities, and began U.S. commercialization of the SimpleScreen CRC blood-based colorectal cancer screening test.
  • These product moves show Abbott Laboratories using the breadth of its nutrition, cardiology and diagnostics platforms to address muscle health, heart failure management and cancer screening at the same time.
  • This article examines how Abbott Laboratories' investment narrative is influenced by this pipeline execution, with a particular focus on the SimpleScreen CRC launch.
Spot 31 resilient stocks with low risk scores that, like Abbott Laboratories, aim to pair healthcare exposure with resilient balance sheets and diversified cash flow streams.

Abbott Laboratories Investment Narrative Recap

To own Abbott Laboratories you need to be comfortable with a broad healthcare platform where glucose monitoring, electrophysiology and cancer diagnostics do a lot of the heavy lifting, while Nutrition is still rebuilding. The key near term swing factor is execution on this pipeline and cost discipline. The recent launches in muscle health, heart failure monitoring and CRC screening look directionally helpful but are unlikely to change that central thesis on their own.

The biggest risk remains pressure on profit margins from legal costs in Nutrition and heavy capital spending, layered on top of a relatively rich P/E versus the U.S. medical equipment group. New product rollouts can support revenue, yet they also require upfront commercial spend, which may keep the timing of margin improvement uncertain if further legal or regulatory actions emerge.

Among the recent news, SimpleScreen CRC is closest to the existing cancer diagnostics story that many investors already watch. It plugs directly into the Exact Sciences backed portfolio and the care gap programs that analysts see as an important earnings driver. The test brings an FDA approved, Medicare covered blood based option that can slot alongside Cologuard Plus and could influence volumes within that franchise over time.

Operationally, SimpleScreen CRC ties into Abbott Laboratories’ broader push in mHealth and remote friendly care. Patient navigation, mobile phlebotomy and digital outreach line up with the same themes behind Libre and CardioMEMS, where connectivity and adherence are central to the catalyst case. The flip side is execution risk. Missteps in scaling support programs or educating clinicians could blunt uptake and soften the margin mix that cancer diagnostics is expected to provide.

Abbott Laboratories Earnings Framework Behind the Product Story

Abbott Laboratories' product headlines only make sense when lined up against the numbers that sit behind the stock. Analysts modeling the business are working off an 8.8% yearly revenue growth rate over the next three years, paired with a planned lift in profit margins from 11.6% today to 16.0% in the same window. Those assumptions matter for how investors judge the payoff from systems like Libre, CardioMEMS and now SimpleScreen CRC, because they frame how much operating leverage the portfolio is expected to produce if the rollouts go to plan.

On earnings, the consensus view points to profit of US$9.6b by 2029, compared with US$5.4b today. That is roughly a US$4.2b increase in absolute terms, which is a large step up in profit dollars that would need to be supported by both new products and tighter cost control. The spread between the most optimistic analysts at US$11.5b and the most cautious at US$6.5b underlines how much disagreement there is on the eventual payoff, especially while Nutrition still carries legal and regulatory overhang from recent settlements.

Pricing expectations also carry a lot of weight in the Abbott Laboratories equity story. To align with the analyst template, the stock would need to trade on a P/E of 26.8x by 2029, using those US$9.6b of forecast earnings. That multiple sits below the current level of 32.9x but above the 24.8x P/E quoted for the GB medical equipment peer group. This setup implies the market is being asked to keep assigning a premium rating to Abbott Laboratories for a long stretch.

Consensus targets put the fair value at US$120.26 against a recent share price of US$102.61, while the published range runs from US$103.00 up to US$135.00. That band gives you a sense of how differently forecasters think about execution on Libre manufacturing expansion, Nutrition margin repair and cancer diagnostics growth. It also highlights why readers should treat the targets as one input in a broader toolkit rather than a roadmap.

Against that backdrop, Abbott Laboratories' narrative ties to forecast revenues of US$60.0b and earnings of US$9.6b by 2029, which implies 8.8% yearly revenue growth and an earnings increase of about US$4.2b from current earnings of US$5.4b.

Uncover why Abbott Laboratories' fair value indicates a 17% potential upside to its current price that could narrow quickly.

NYSE:ABT 1-Year Stock Price Chart
NYSE:ABT 1-Year Stock Price Chart

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community span roughly US$80 to just over US$120, so some retail investors see Abbott Laboratories as stretched, while others view it closer to a bargain. Weigh that spread against legal overhangs and the pending earnings report, then explore several competing viewpoints before deciding how Abbott fits your portfolio.

Explore 5 other Abbott Laboratories fair value estimates, including one that suggests as much as 22% downside from the current price.

Form Your Own Verdict

Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

Looking For More Investment Ideas Beyond Abbott Laboratories?

If Abbott Laboratories' mix of healthcare exposure and diversified income streams appeals to you, it can be useful to line it up against other listed businesses with different risk and return profiles using the Simply Wall St Screener.

  • If you want to focus on quality at a reasonable price, compare Abbott against a wider pool of companies through the 30 high quality undervalued stocks that may align better with your return and risk goals.
  • For investors who care most about balance sheet strength, set Abbott alongside a list of solid balance sheet and fundamentals (25 results) to see which businesses pair defensive finances with consistent fundamentals.
  • Income focused readers can benchmark Abbott against a universe of high yield opportunities by scanning 8 dividend fortresses that prioritise sizeable payouts with a focus on durability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.